The debate highlighted broad cellular toxicity of existing HSP inhibitors but did not resolve how to engineer selectivity for tau-associated chaperones. This structure-activity relationship gap prevents rational drug design.
Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)
Allosteric modulators targeting cryptic sites in HSP90's C-terminal domain that are uniquely accessible when HSP90 is bound to tau-containing complexes, selectively destabilizing tau-HSP90 interactions while preserving essential client protein folding.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID7 mediumValidation: 0%5 supporting / 2 opposing
✓For(5)
5
2
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
2
1
MECH 4CLIN 2GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Folding or holding?-Hsp70 and Hsp90 chaperoning of…
Pharmacological mechanism and therapeutic efficacy of Icariside II in the treatment of acute ischemic stroke: …MEDIUM▼
Pharmacological mechanism and therapeutic efficacy of Icariside II in the treatment of acute ischemic stroke: a systematic review and network pharmacological analysis.
Mapping the pathogenic nexus: Gene overlap and protein interaction networks in Alzheimer's and breast cancer a…MEDIUM▼
Mapping the pathogenic nexus: Gene overlap and protein interaction networks in Alzheimer's and breast cancer as a precursor to protein structure prediction and analysis.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-10 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Therapeutic Hypotheses for HSP70/HSP90 Inhibitor Tau-Selectivity
Hypothesis 1: Allosteric Pocket Exploitation for Tau-Specific HSP90 Modulation
Target: HSP90 C-terminal domain allosteric sites
The minimal structural requirement for tau-selectivity involves targeting previously unexploited allosteric pockets in HSP90's C-terminal domain that are uniquely accessible when HSP90 is bound to tau-containing complexes. Unlike ATP-competitive inhibitors that disrupt all HSP90 functions, allosteric modulators binding to these cryptic sites would selectively destabilize tau-HSP90 intera
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll provide a rigorous critique of each hypothesis based on fundamental principles of protein biochemistry, drug development, and neurobiology. Let me analyze the specific weaknesses, alternative explanations, and experimental approaches needed to falsify these claims.
Hypothesis 1: Allosteric Pocket Exploitation for Tau-Specific HSP90 Modulation
Critical Weaknesses:
Overstated selectivity assumption: The hypothesis assumes HSP90 adopts unique conformations when bound to tau that are fundamentally different from other client proteins. However, HSP90 client binding involves co
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
I'll assess the practical feasibility of these HSP70/HSP90 inhibitor hypotheses from a drug development perspective, focusing on druggability, existing chemical matter, competitive landscape, and development challenges.
Overall Market Context & Competitive Landscape
Current HSP90 Inhibitor Landscape: The HSP90 inhibitor field has seen significant commercial failures despite promising preclinical data:
Geldanamycin derivatives (17-AAG, 17-DMAG): Abandoned due to hepatotoxicity and limited efficacy
Ganetespib (Synta Pharmaceuticals): Failed multiple Phase III trials in lung
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF P301S transgenic mice are treated daily with an allosteric HSP90 modulator (e.g., compound SDA-001) at 10 mg/kg for 28 days, THEN a ≥30% reduction in detergent‑soluble tau levels in brain tissue will be observed relative to vehicle‑treated mice within 2 weeks after the final dose.
pendingconf: 0.70
Expected outcome: Brain detergent‑soluble tau concentration (ELISA) decreases by ≥30 % versus vehicle control.
Falsified by: No significant reduction in tau levels (≤10 % change) or concurrent alteration of known HSP90 client proteins (e.g., AKT, ERK) by >20 %.
Method: In vivo pharmacodynamic study in P301S tau transgenic mice (JAX #006214) with daily oral dosing and sequential brain sampling at baseline, day 14, and day 28.
IF human iPSC‑derived cortical neurons overexpressing 2N4R tau are treated with 1 µM of the allosteric HSP90 modulator for 48 h, THEN tau‑HSP90 co‑immunoprecipitation will be reduced by ≥50 % relative to DMSO control, while total HSP90 ATPase activity remains unchanged (±10 %).
pendingconf: 0.65
Expected outcome: Co‑IP densitometry shows ≥50 % decrease in tau‑HSP90 complex; HSP90 ATPase assay shows no >10 % inhibition.
Falsified by: No change in tau‑HSP90 interaction (≤20 % reduction) or significant inhibition of HSP90 ATPase activity (>30 % decrease).
Method: iPSC‑derived cortical neurons (WiCell WTC11 line) seeded in 96‑well plates, treated for 48 h, followed by co‑immunoprecipitation and a colorimetric ATPase activity assay.